Portal de Periódicos da CAPES

Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach

2023; American Medical Association; Volume: 148; Issue: 3 Linguagem: Inglês

10.5858/arpa.2022-0443-oa

1543-2165

Susana Hernández, Esther Conde, Aída Molero, Ana Suárez‐Gauthier, Rebeca Martínez, Marta Alonso de la Varga, Carlos Plaza, Carmen Leis Camacho, Débora Chantada, Laura Juaneda-Magdalena, Enrique García-Toro, Patricia Saiz-Lopez, Federico Rojo, Mar Abad, Valentina Boni, Sofía del Carmen, Rita María Regojo, Marina Sánchez‐Frías, Cristina Teixidó, Luis Paz‐Ares, Fernando López‐Ríos,

Medical Imaging Techniques and Applications

The neurotrophic tropomyosin receptor kinase (NTRK) family gene rearrangements have been recently incorporated as predictive biomarkers in a "tumor-agnostic" manner. However, the identification of these patients is extremely challenging because the overall frequency of NTRK fusions is below 1%. Academic groups and professional organizations have released recommendations on the algorithms to detect NTRK fusions. The European Society for Medical Oncology proposal encourages the use of next-generation sequencing (NGS) if available, or alternatively immunohistochemistry (IHC) could be used for screening with NGS confirmation of all positive IHC results. Other academic groups have included histologic and genomic information in the testing algorithm.